![]() |
|
|
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
|||||||||||
|
![]() |
|
||||||||
|
Human FANCD2 | |
Mouse | |
Human (tested or 100% immunogen sequence identity) | |
IgG Monoclonal [103] | |
Unconjugated | |
Protein G purified | |
Unmodified |
FANCD2 antibody was raised against fusion protein from human FANCD2. | |
Human FANCD2 fusion protein | |
Immunohistochemistry: LS-B195 was validated for use in immunohistochemistry on a panel of 21 formalin-fixed, paraffin-embedded (FFPE) human tissues after heat induced antigen retrieval in pH 6.0 citrate buffer. After incubation with the primary antibody, slides were incubated with biotinylated secondary antibody, followed by alkaline phosphatase-streptavidin and chromogen. The stained slides were evaluated by a pathologist to confirm staining specificity. The optimal working concentration for LS-B195 was determined to be 2.5 ug/ml. |
PBS, pH 7.2, Contains no preservative. | |
+4°C or -20°C, Avoid repeated freezing and thawing. | |
For research use only. |
FANCD2 Antibody, FA-D2 Antibody, FAD Antibody, FACD Antibody, FA4 Antibody, FAD2 Antibody, FANCD Antibody, Protein FACD2 Antibody
The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair.
|